Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations.

Remington G, Mann S, McCormick P, Nobrega JN, Hahn M, Natesan S.

Pharmacol Biochem Behav. 2011 Nov;100(1):86-9. doi: 10.1016/j.pbb.2011.07.019. Epub 2011 Aug 3.

PMID:
21839766
2.

Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.

van der Zwaal EM, Luijendijk MC, Adan RA, la Fleur SE.

Eur J Pharmacol. 2008 May 6;585(1):130-6. doi: 10.1016/j.ejphar.2007.11.078. Epub 2008 Mar 4. Review.

PMID:
18378227
3.

[Therapeutic systems and drug delivery. 4. The osmotic minipump].

Davila D.

Lijec Vjesn. 1992 Jan-Apr;114(1-4):62-7. Review. Croatian.

PMID:
1343031
4.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
5.

Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.

Belgamwar RB, Fenton M.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003729. Review.

PMID:
15846678
6.

Olanzapine for schizophrenia.

Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S.

Cochrane Database Syst Rev. 2003;(1):CD001359. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD001359.

PMID:
12535408
7.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
8.

Olanzapine for schizophrenia.

Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD001359. Review.

PMID:
15846619
9.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
10.

Olanzapine for schizophrenia.

Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S.

Cochrane Database Syst Rev. 2000;(2):CD001359. Review. Update in: Cochrane Database Syst Rev. 2003;(1):CD001359.

PMID:
10796640
11.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
12.

New generation antipsychotics for first episode schizophrenia.

Rummel C, Hamann J, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2003;(4):CD004410. Review.

PMID:
14584012
13.

Risperidone versus olanzapine for schizophrenia.

Jayaram MB, Hosalli P.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD005237. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD005237.

PMID:
15846745
14.

Antipsychotics for delirium.

Lonergan E, Britton AM, Luxenberg J, Wyller T.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005594. Review.

PMID:
17443602
15.

[Pharmaceutical formulations and adherence to pharmacological treatment in psychiatry: the example of oral disintegrating tablet of olanzapine].

Cecchi C, Canonico PL.

Riv Psichiatr. 2012 Jan-Feb;47(1):30-9. doi: 10.1708/1034.11289. Review. Italian.

PMID:
22358215

Supplemental Content

Support Center